Daily SPAC Update – August 19, 2024

by | Aug 19, 2024

NOVV Deal Vote Set. CVII Terminates Deal and Will Liquidate. FEXD To Liquidate. YOTA Vote Adjourned to August 20.

 Boardroom Alpha SPAC Resources
– Full SPAC Listing
– SPAC SEC Filings
– Boardroom Alpha IPO & SPAC Intelligence Platform (7-Day Trial)

Daily SPAC Update

SPAC DEAL & EXTENSION VOTES SET
NOVV – Nova Vision Acquisition Corp * DEAL VOTE SET: Sep 10, 2024 * trust $12.23

SPAC DEAL TERMINATIONS (Last 10 Days)
2024-08-18: CVII + CorpAcq
2024-08-15: ADRT + GIGA TRONICS INC

OTHER SPAC NEWS
FEXD – FINTECH ECOSYSTEM DEVELOPMENT CORP * Liquidation-> 2024-08-29 * trust $10.69
HAIA – HEALTHCARE AI ACQUISITION CORP * Merger Agreement
IRRX – INTEGRATED RAIL & RESOURCES ACQUISITION CORP * Merger Agreement
YOTA – YOTTA ACQUISITION CORP * Vote Adjourn

YESTERDAY’S TOP SPAC GAINERS
9.01% ~ $ 12.22 | QOMO – Qomolangma Acquisition Corp. (Pre-Deal)
4.91% ~ $ 12.60 | NPAB – New Providence Acquisition Corp. II (Pre-Deal)
1.58% ~ $ 11.80 | BYNO – byNordic Acquisition Corporation (Pre-Deal)

YESTERDAY’S TOP SPAC LOSERS
-15.80% ~ $ 12.63 | ADRT – Ault Disruptive Technologies Corp (Pre-Deal)
-10.53% ~ $ 10.03 | IFIN – InFinT Acquisition Corporation (Announced)
-4.02% ~ $ 10.97 | FEXD – Fintech Ecosystem Development Corp. (Announced)
-1.77% ~ $ 12.18 | CLOE – Clover Leaf Capital Corp. (Announced)
-1.52% ~ $ 11.69 | ALSA – Alpha Star Acquisition Corp (Pre-Deal)

NEW SPAC IPOs
Aug 16: SBXD – Silverbox Corp Iv $200M IPO
Aug 16: HOND – Hcm Ii Acquisition Corp. $200M IPO

LATEST SPAC IPO PERFORMANCE
Aug 16 | $ 9.98 | HOND – HCM II Acquisition Corp.
Aug 16 | $ 9.99 | SBXD – SilverBox Corp IV
Aug 09 | $ 9.98 | VACH – Voyager Acquisition Corp
Aug 06 | $ 9.94 | EQV – EQV Ventures Acquisition Corp.
Aug 01 | $ 10.02 | MBAV – M3-Brigade Acquisition V Corp.
Aug 01 | $ 10.00 | AAM – AA Mission Acquisition Corp.
Jul 24 | $ 10.06 | DTSQ – DT Cloud Star Acquisition Corp

Recent Analysis

Daily SPAC Update – January 15, 2025

$150M Plum Acquisition IV and $50M Ribbon Acquisition SPAC IPOs. Aimfinity (AIMAU) and Quetta (QETA) Extensions Approved. Bowen (BOWN) + Qianzhi BioTech Deal Approved. 

Daily SPAC Update – January 14, 2025

Cohen Circle (CCIR) LOI with Ukranian Firm. BRKH DeSPACs to Blaize (BZAI). PPYA Extension Vote. Aimfinity Extends to Oct 2025. Bowen Acquisition (BOWN) Forward Purchase Agreement. 

Daily SPAC Update – January 9, 2025

FutureTech II (FTII) Trust Overpayments Continue. Aimfinity Investment (AIMAU) Sets Extension Vote. Western Acquisition (WAVS) Extension Approved. Global Star (GLST) Deal Vote Set. RANG/RANGU Separate Trading on Jan 13.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.